Clinical Trials
11 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02642042 2026-05-29
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03340506 2026-04-20
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT05358249 2026-04-14
KontRASt-03
Novartis
Phase 1/2 Active not recruiting
NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT03225664 2026-01-16
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
NCT04452877 2026-01-13
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
Phase 2 Completed